Belén Garijo

Chief Executive Officer, Healthcare; Member of the Executive Board, Merck

Belén Garijo is a Member of the Executive Board of Merck since January 2015. She is responsible for the Healthcare business sector and since 2013, she has acted as President and CEO of the Biopharma business, where she started in 2011 as Chief Operating Officer. In September 2017, Belén Garijo also assumed Executive Board responsibility for Group Human Resources.

Before joining Merck, Belén Garijo served as the Senior Vice President Global Operations Europe at Sanofi-Aventis, where she was also a member of the Management Committee of the Sanofi-Aventis Group and of the Management Board of the Sanofi-Pasteur vaccines joint venture with MSD. In 2011, she took on the additional role of Global Integration Leader for the Genzyme acquisition. From 2003 to 2006, Belén Garijo was General Manager of Aventis Spain, subsequently leading the merger of Sanofi-Aventis in 2004. From 2000 to 2003, she served as Global Vice President Oncology at Aventis and from 1996 as Director of the Oncology Business Unit in the predecessor company Rhône-Poulenc Rorer.

Prior to this she worked in R&D for eight years, initially as the Medical Director of the Abbott Laboratories Spanish affiliate, before moving to lead International Medical Affairs at the Abbott headquarters in Illinois, USA.

Belén Garijo is a medical doctor, specialized in clinical pharmacology. She worked as a practicing physician for six years before moving to the pharmaceutical industry.

Most Popular

COVID-19

ジェンダー不平等を拡大する介護の在り方を浮き彫りにした、新型コロナウイルス

新型コロナウイルスの大流行により介護の必要性が増し、予期せぬ大きな課題が提起される中、介護者を認識し、評価し、性差による偏向を減らしていくことの緊急性が高まっています。特に、リソースが限られ、患者の多くが入院できない状況において、新型コロナウイルスの患者とその家族にとって、緩和ケアおよび終末期ケアは必要性の高いものとなると考えられます。

18 May 2020